Rivaroxaban in Chinese children with giant coronary artery aneurysms after Kawasaki disease
Bibliographic record
Abstract
Background: Data on the use of rivaroxaban in children with giant coronary artery aneurysm (GCAA) after Kawasaki disease (KD) remain limited. Objectives: This study evaluated the feasibility of rivaroxaban in Chinese children with GCAA after KD. Methods: This study was conducted at the Children's Hospital of Fudan University. Children aged 1 month to 18 years with persistent GCAA (diameter ≥ 8 mm or Z-score ≥ 10) during the postacute period of KD were included and followed up for at least 6 months. The study consisted of 2 stages. During the first stage (January-December 2023), patients received rivaroxaban following the 20-mg-equivalent regimen. In the second stage (January-November 2024), a pharmacometric model-informed rivaroxaban regimen was implemented. The primary outcome was a composite of GCAA thrombosis and major adverse cardiovascular event within 6 months. The secondary outcome included major bleeding and clinically relevant nonmajor (CRNM) bleeding. Results: In the first stage, 6 patients were enrolled (median age, 14.6 months; range, 4.7-130.8 months; median weight, 9.9; range, 6.6-33 kg; Z-score, 14.9; range, 10.6-28.0). No primary outcome or major bleeding occurred. Four CRNM bleedings were documented, leading to 6 dose adjustments. Two patients discontinued rivaroxaban due to improved coronary status. In the second stage, 14 patients received the 15-mg-equivalent rivaroxaban regimen (median age, 69.7 months; range, 16.4-143.1 months; median weight, 19.5 kg; range, 12.5-57.5 kg; Z-score, 14.7; range, 10.6-39.1). No primary or secondary outcome occurred. Two patient important bleeding no intervention events were documented. All patients remained on rivaroxaban beyond 6 months. External validation supported the predictive performance of model extrapolation. Conclusion: The 15-mg-equivalent rivaroxaban regimen appeared feasible in Chinese children with GCAA after KD, with no GCAA thrombosis, major bleeding or CRNM bleeding observed within 6 months. Larger studies are required to confirm these preliminary findings.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.001 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.001 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.001 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".